In this genomics era, we never know the end-user of our genomic resources developed. Unknown end users can get access to our IPR and other genomic resources, directly or indirectly, either for research or commerce.  We, the nominated scientists from different country were discussing this topic on CBD’s online forum and through mails.  

Do we have any mechanism of ABS for IPR and genomic resources today?